Merck continues to grapple with a downturn in
Gardasil sales in China and Japan causing stocks to reverse course. Despite perceived 'woes,' recent
cancer drug data and Q1 earnings reports that topped estimates have seen a boost to stocks. Thestocks are currently deemed a good buy by asset manager
Marjorie Taylor Greene and billionaire
Ken Fisher. While uncertainty continues around HPV vaccines, a potential
M&A deal with SpringWorks Therapeutics and positive Q1 results have held stock reasonably steady.
Halozyme patent litigation and trading flat post Q1 results show some challenges faced.
MRK's inclusion in Prem Watsa’s, Ken Fisher’s stock picks and the bestlar value stocks amongst large-caps indicates investor confidence. The stocks have shown volatility, touching a 52-week low amid market pressures. Despite a threatened increase in costs from tariffs, dividend payout plans are intact. Upcoming shareholder proposals ahead of the annual meeting indicates ongoing stakeholder scrutiny.
Merck Stocks News Analytics from Fri, 17 Jan 2025 08:00:00 GMT to Sat, 26 Apr 2025 18:32:00 GMT -
Rating 7
- Innovation -1
- Information 5
- Rumor 0
